Payment overview · 2025
General Payments
$525.51
23 reported records · 6 companies
Healthcare provider profile · identity verified
Stanton P Tripodis, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CLEARWATER, FL · NPI 1528011285
Verified facts
What the public records show
CMS Open Payments records show Stanton P Tripodis, MD received $525.51 in general payments during 2025 across 23 reported records.
Novo Nordisk Inc accounted for 40.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $210.17 | 40.0% | 12 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $175.27 | 33.4% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $85.47 | 16.3% | 5 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $20.68 | 3.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.76 | 3.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.16 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $525.51 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $191.75 | 10 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $175.27 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $81.01 | 9 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $55.71 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $29.76 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $20.68 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.76 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.76 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.42 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.16 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Alprazolam | Alprazolam | 486 | 114 |
| Amlodipine Besylate | Amlodipine Besylate | 444 | 115 |
| Atorvastatin Calcium | Atorvastatin Calcium | 358 | 95 |
| Levothyroxine Sodium | Levothyroxine Sodium | 346 | 95 |
| Losartan Potassium | Losartan Potassium | 280 | 75 |
| Lisinopril | Lisinopril | 264 | 75 |
| Simvastatin | Simvastatin | 236 | 69 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 221 | 64 |
| Omeprazole | Omeprazole | 217 | 66 |
| Pantoprazole Sodium | Pantoprazole Sodium | 211 | 70 |
| Metformin Hcl | Metformin Hcl | 209 | 61 |
| Gabapentin | Gabapentin | 206 | 57 |
| Tamsulosin Hcl | Tamsulosin Hcl | 194 | 55 |
| Famotidine | Famotidine | 184 | 55 |
| Hydrochlorothiazide | Hydrochlorothiazide | 167 | 46 |
| Zolpidem Tartrate | Zolpidem Tartrate | 165 | 39 |
| Furosemide | Furosemide | 151 | 44 |
| Donepezil Hcl | Donepezil Hcl | 131 | 37 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 128 | 24 |
| Tramadol Hcl | Tramadol Hcl | 126 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 125 | 39 |
| Potassium Chloride | Potassium Chloride | 123 | 37 |
| Lovastatin | Lovastatin | 114 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 109 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 109 | 28 |
| Azithromycin | Azithromycin | 100 | 84 |
| Allopurinol | Allopurinol | 99 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 98 | 33 |
| Lorazepam | Lorazepam | 96 | 22 |
| Trazodone Hcl | Trazodone Hcl | 96 | 27 |
| Finasteride | Finasteride | 89 | 26 |
| Memantine Hcl | Memantine Hcl | 86 | 18 |
| Meloxicam | Meloxicam | 81 | 26 |
| Pioglitazone Hcl | Pioglitazone Hcl | 75 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 71 | 24 |
| Clonazepam | Clonazepam | 69 | 19 |
| Sertraline Hcl | Sertraline Hcl | 68 | 23 |
| Eliquis | Apixaban | 67 | 15 |
| Montelukast Sodium | Montelukast Sodium | 66 | 23 |
| Carvedilol | Carvedilol | 64 | 18 |
| Alendronate Sodium | Alendronate Sodium | 62 | 20 |
| Temazepam | Temazepam | 61 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 55 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 55 | 17 |
| Diazepam | Diazepam | 54 | 16 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 53 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 53 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 53 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 52 | 38 |
| Synthroid | Levothyroxine Sodium | 52 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 50 | 29 |
| Atenolol | Atenolol | 50 | 11 |
| Methylprednisolone | Methylprednisolone | 48 | 43 |
| Ropinirole Hcl | Ropinirole Hcl | 48 | 19 |
| Dicyclomine Hcl | Dicyclomine Hcl | 47 | 18 |
| Creon | Lipase/Protease/Amylase | 43 | 11 |
| Ibuprofen | Ibuprofen | 43 | 13 |
| Benazepril Hcl | Benazepril Hcl | 42 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 42 | 19 |
| Glipizide Er | Glipizide | 41 | 11 |
| Ozempic | Semaglutide | 41 | suppressed |
| Pregabalin | Pregabalin | 40 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 39 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 38 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 38 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 38 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 36 | suppressed |
| Spironolactone | Spironolactone | 36 | 12 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 35 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 34 | 29 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 34 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 33 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 33 | 11 |
| Irbesartan | Irbesartan | 33 | suppressed |
| Nifedipine Er | Nifedipine | 33 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 32 | suppressed |
| Glipizide | Glipizide | 32 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 32 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | suppressed |
| Ezetimibe | Ezetimibe | 31 | suppressed |
| Prednisone | Prednisone | 31 | 21 |
| Acyclovir | Acyclovir | 30 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 30 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 29 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 24 |
| Celecoxib | Celecoxib | 28 | 12 |
| Fenofibrate | Fenofibrate | 28 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | suppressed |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 27 | 12 |
| Hydrocortisone | Hydrocortisone | 26 | 15 |
| Sucralfate | Sucralfate | 26 | 11 |
| Azelastine Hcl | Azelastine Hcl | 25 | suppressed |
| Estradiol | Estradiol | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 15 |
| Amoxicillin | Amoxicillin | 23 | 20 |
| Farxiga | Dapagliflozin Propanediol | 23 | suppressed |
| Bumetanide | Bumetanide | 22 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 22 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Cephalexin | Cephalexin | 21 | 18 |
| Glimepiride | Glimepiride | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Linzess | Linaclotide | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Metronidazole | Metronidazole | 18 | 15 |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 16 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 14 |
| Valsartan | Valsartan | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Cefprozil | Cefprozil | 13 | suppressed |
| Ciclopirox | Ciclopirox | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Nadolol | Nadolol | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $525.51 · 23 records | Novo Nordisk Inc | AIRSUPRA, CAPVAXIVE, FARXIGA, INGREZZA, MOUNJARO, Ozempic, Rybelsus, SHINGRIX, Wegovy, ZEPBOUND | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error